Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UIC201604
- Development stage
- Phase 1
- Lead developer
- Korea United Pharm
01
Overview
UIC201604 is an investigational drug developed by Korea United Pharm. Its precise mechanism of action, molecular modality, and therapeutic class have not been disclosed in public sources. The compound has been studied in early-phase clinical trials, specifically for its safety and pharmacokinetics when co-administered with another investigational agent, UIC201603, in healthy volunteers. There are no approved indications or known adverse events reported for this drug as of the latest available data[1][2][3][4].
Beyond the preview
Go deeper on UIC201604.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UIC201604.